Simulating demand for innovative radiotherapies: An illustrative model based on carbon ion and proton radiotherapy

Radiotherapy and Oncology

Volumn 96, Issue 2, 2010, Pages 243-249

  Pommier, Pascal ^a   Lievens, Yolande ^b   Feschet, Fabien ^c   Borras, Josep M ^d   Baron, Marie Hélne ^e   Shtiliyanova, Anastasiya ^c   Pijls Johannesma, Madelon ^f  

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d Hospitalet   (Spain)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carbon ions; Decision making; Innovation; Modelling; Protons; Recruitment

Indexed keywords

CARBON; PROTON;

ARTICLE; CANCER RADIOTHERAPY; CHORDOMA; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EXPERIMENTAL THERAPY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HUMAN; ION THERAPY; MULTICENTER STUDY; NEOPLASM; PARTICLE RADIATION; PATIENT REFERRAL; PRIORITY JOURNAL; PROTON THERAPY; RADIATION EQUIPMENT; SIMULATION; SKULL BASE CHORDOMA; SKULL BASE TUMOR; SKULL CHONDROSARCOMA; TREATMENT INDICATION; TUMOR CLASSIFICATION;

CARBON; COMPUTER SIMULATION; DECISION SUPPORT TECHNIQUES; HUMANS; IONS; PROTONS; RADIATION ONCOLOGY; RADIOTHERAPY;

EID: 77955712245     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.04.010     Document Type: Article

References (44)

1. M. Brada, M. Pijls-Johannesma, and D. De Ruysscher Proton therapy in clinical practice: current clinical evidence J Clin Oncol 25 2007 965 970
2. C. Greco, and S. Wolden Current status of radiotherapy with proton and light ion beams Cancer 109 2007 1227 1238
3. D. Schulz-Ertner, and H. Tsujii Particle radiation therapy using proton and heavier ion beams J Clin Oncol 25 2007 953 964
4. M. Goitein, and M. Jermann The relative costs of proton and X-ray radiation therapy Clin Oncol (R Coll Radiol) 15 2003 S37 S50
5. Y. Lievens, and B.W. van den Proton beam therapy: too expensive to become true? Radiother Oncol 75 2005 131 133
6. M. Pijls-Johannesma, P. Pommier, and Y. Lievens Cost-effectiveness of particle therapy: current evidence and future needs Radiother Oncol 89 2008 127 134
7. H. Suit The Gray Lecture 2001: coming technical advances in radiation oncology Int J Radiat Oncol Biol Phys 53 2002 798 809
8. K. Kesteloot, Y. Lievens, and S.E. van der Improved management of radiotherapy departments through accurate cost data Radiother Oncol 55 2000 251 262
9. B.J. Kobeissi, M. Gupta, and C.A. Perez Physician resource utilization in radiation oncology: a model based on management of carcinoma of the prostate Int J Radiat Oncol Biol Phys 40 1998 593 603
10. Y. Lievens, B.W. van den, and K. Kesteloot Activity-based costing: a practical model for cost calculation in radiotherapy Int J Radiat Oncol Biol Phys 57 2003 522 535
11. C.A. Perez, B. Kobeissi, and B.D. Smith Cost accounting in radiation oncology: a computer-based model for reimbursement Int J Radiat Oncol Biol Phys 25 1993 895 906
12. P. Pommier, L. Zucca, and I. Naslund Light ion facility projects in Europe: methodological aspects for the calculation of the treatment cost per protocol Radiother Oncol 73 2004 S183 S185
13. M.H. Baron, P. Pommier, and V. Favrel A "one-day survey": as a reliable estimation of the potential recruitment for proton- and carbon-ion therapy in France Radiother Oncol 73 2004 S15 S17
14. R. Mayer, U. Mock, and R. Jager Epidemiological aspects of hadron therapy: a prospective nationwide study of the Austrian project MedAustron and the Austrian Society of Radiooncology (OEGRO) Radiother Oncol 73 2004 S24 S28
15. U. Mock, R. Mayer, and R. Potter The med AUSTRON/OGRO patterns of care study on radiotherapy indications in Austria Radiother Oncol 73 2004 S29 S34
16. L. Remontet, J. Esteve, and A.M. Bouvier Cancer incidence and mortality in France over the period 1978-2000 Rev Epidemiol Sante Publique 51 2003 3 30
17. Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ 2009.
18. M.J. Buxton Economic evaluation and decision making in the UK Pharmacoeconomics 24 2006 1133 1142
19. M.F. Drummond, B.J. O'Brien, G.L. Stoddart, and G.W. Torrance Methods for the economic evaluation of health care programs 1997 Oxford University Press Oxford
20. C. Hoffmann, and J.M. Graf von der Schulenburg The influence of economic evaluation studies on decision making. A European survey. The EUROMET group Health Policy 52 2000 179 192
21. M. Johannesson Economic evaluation of drugs and its potential uses in policy making Pharmacoeconomics 8 1995 190 198
22. P. Tappenden, J. Chilcott, and S. Ward Methodological issues in the economic analysis of cancer treatments Eur J Cancer 42 2006 2867 2875
23. S. Walker, S. Palmer, and M. Sculpher The role of NICE technology appraisal in NHS rationing Br Med Bull 81-82 2007 51 64
24. M.C. Weinstein, and W.B. Stason Foundations of cost-effectiveness analysis for health and medical practices N Engl J Med 296 1977 716 721
25. Williams I, McIver S, Moore D, Bryan S. The use of economic evaluations in NHS decision-making: a review and empirical investigation. Health Technol Assess 2008;12:iii, ix-iii, 175.
26. C. Buron, B. Le Vu, and J.M. Cosset Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study Int J Radiat Oncol Biol Phys 67 2007 812 822
27. E.C. Halperin Overpriced technology in radiation oncology Int J Radiat Oncol Biol Phys 48 2000 917 918
28. Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technol Assess 2003;7:iii, ix-iii, 157.
29. R. Remonnay, M. Morelle, P. Pommier, F. Giammarile, and M.O. Carrere Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making Int J Technol Assess Health Care 24 2008 212 220
30. E.C. Halperin Randomized prospective trials of innovative radiotherapy technology are necessary J Am Coll Radiol 6 2009 33 37
31. H. Suit, S. Goldberg, and A. Niemierko Proton beams to replace photon beams in radical dose treatments Acta Oncol 42 2003 800 808
32. H. Suit, H. Kooy, and A. Trofimov Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No Radiother Oncol 86 2008 148 153
33. C.D. Naylor Grey zones of clinical practice: some limits to evidence-based medicine Lancet 345 1995 840 842
34. W. Rosenberg, and A. Donald Evidence based medicine: an approach to clinical problem-solving BMJ 310 1995 1122 1126
35. B. Huang, M. Dignan, D. Han, and O. Johnson Does distance matter? Distance to mammography facilities and stage at diagnosis of breast cancer in Kentucky J Rural Health 25 2009 366 371
36. T. Iversen, and G.S. Kopperud Regulation versus practice - the impact of accessibility on the use of specialist health care in Norway Health Econ 14 2005 1231 1238
37. P.E. Marik, A. Rakusin, and S.S. Sandhu The impact of the accessibility of cranial CT scans on patient evaluation and management decisions J Intern Med 241 1997 237 243
38. E. Pagano, D. Di Cuonzo, and C. Bona Accessibility as a major determinant of radiotherapy underutilization: a population based study Health Policy 80 2007 483 491
39. K. Wilson, and M.W. Rosenberg Accessibility and the Canadian health care system: squaring perceptions and realities Health Policy 67 2004 137 148
40. G.H. Roberts, P.B. Dunscombe, and R.S. Samant Geographic delivery models for radiotherapy services Australas Radiol 46 2002 290 294
41. P. Dunscombe, G. Roberts, and J. Walker The cost of radiotherapy as a function of facility size and hours of operation Br J Radiol 72 1999 598 603
42. T. Hindle, E. Roberts, and D. Worthington Specialty location decisions in the reformed NHS: a case study Health Serv Manage Res 11 1998 174 181
43. M. Noether Competition among hospitals J Health Econ 7 1988 259 284
44. A. Tay Assessing competition in hospital care markets: the importance of accounting for quality differentiation Rand J Econ 34 2003 786 814